EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials
Elevating the role of APPs as partners in the clinic will help to reinforce the important role clinical trials play in cancer care and strengthen accrual efforts
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
The Group is recognizing Dr. Forde as an exceptional physician-scientist who is making significant research contributions as a translational thoracic cancer investigator